Actinium Pharmaceuticals Inc. (ATNM) 10.17 $ATNM
Actinium Announces Start of Collaboration to Manufacture Iomab(TM)-B for Phase 3 Clinical Trial and Commercialization
Business Wire - Tue May 06, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it made further steps towards centralized current good manufacturing practice ("cGMP" manufacturing of its lead drug candidate Iomab(TM)-B. The Company engaged IBA Molecular North America, Inc. to scale up under cGMPs, the production of Iomab(TM)-B and further develop and validate the quality control testing of the product.
Actinium to Present at the Sidoti Micro-Cap Conference in NYC on May 9
Business Wire - Mon May 05, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will participate in the Sidoti Ninth Annual Micro-Cap Conference in New York City on May 9, 2014.
Actinium Announces Key Additions to Senior Management Team
Business Wire - Mon Apr 28, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of four new additions to the senior management team. As Actinium's drug candidates continue to advance through the clinic, these hires are timely and expected to enable the Company to maximize the value of its assets. Capabilities are being added in clinical operations, regulatory affairs, quality assurance, finance and communications. Actinium gains business development and investor relations expertise as well, as the Company raises its profile in the investment community. These four hires bring to the Company a robust and complementary set of healthcare industry experience, product development skills, regulatory compliance, and communications acumen.
Actinium to Present at RedChip Global Online CEO Conference April 24
Business Wire - Thu Apr 24, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 12:30 PM ET at RedChip's Global Online CEO Conference. Dr. Kaushik J. Dave, President and CEO will present a corporate update.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Apr 17, 8:20AM CDT
RedChip Companies, Inc. ("RedChip", an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, April 17, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, April 19, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Saturday, April 19, 2014 at 3:30 p.m. GMT, and Sunday, April 20, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday April 20, 2014 at 3:30 p.m. HKT.
Actinium Pharmaceuticals, Inc. Analyst Report: High Potential Emerging Biopharmaceutical Firm Nearing Phase 3 Trial Commencement for Innovative Cancer Treatments
PR Newswire - Thu Apr 10, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications.
Actinium Announces Further Development of Actimab-A Manufacturing
Business Wire - Mon Apr 07, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it started a collaboration with IsoTherapeutics Group of Houston, TX to complete studies required for introduction of a new manufacturing process for Actimab-A. The new manufacturing process that results in a tenfold improvement of manufacturing yield has been developed by the Company internally in collaboration with IsoTherapeutics. IsoTherapeutics will perform additional experiments to generate documentation necessary for regulatory submissions.
Actinium CEO Interviewed for "Small Stocks: Big Money" Airing on Fox Business and Bloomberg
Business Wire - Thu Apr 03, 12:15PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces the availability of an exclusive interview with its President and CEO, Kaushik J. Dave, Ph.D.
Actinium's shares listed on NYSE MKT to facilitate increased visibility and liquidity
M2 - Thu Mar 27, 5:14AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) revealed on Wednesday that its shares have begun trading as of 26 March 2014 on the NYSE MKT under the symbol "ATNM".
Actinium Commences Trading on NYSE MKT Today under the Symbol ATNM
Business Wire - Wed Mar 26, 8:30AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that its shares have commenced trading today on the NYSE MKT under the symbol "ATNM". The company formerly traded on the OTCQB under the same symbol.
Actinium to Commence Trading on NYSE MKT on March 26, 2014
Business Wire - Tue Mar 25, 9:05AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will commence trading its common shares on the NYSE MKT beginning on March 26, 2014.
Actinium to Present at BioCentury 21st Annual Future Leaders in the Biotech Industry Conference on March 28
Business Wire - Tue Mar 25, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the BioCentury 21st Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 8:30 am Eastern Time.
Actinium to begin trading on NYSE MKT on 26 March 2014
M2 - Tue Mar 25, 4:16AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) disclosed on Monday that it will commence trading on the New York Stock Exchange on 26 March 22014.
Actinium Pharmaceuticals' Actimab-A drug candidate enters ongoing Phase 1/2 trial for newly diagnosed AML patients
M2 - Tue Mar 25, 4:06AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) said on Monday that it has treated the first patient with Actimab-A drug candidate for newly diagnosed AML patients under its ongoing Phase 1/2 trial.
Actinium to List Common Stock on NYSE MKT
Business Wire - Mon Mar 24, 4:20PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on March 26, 2014. The Company will continue to trade under the symbol "ATNM" but will withdraw its shares from listing on the OTCQB concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.
Actinium Announces Introduction of the New Lot of Lintuzumab into the Clinic
Business Wire - Mon Mar 24, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the first patient was successfully treated with Actimab-A drug candidate manufactured with the new lot of Lintuzumab, the antibody that provides the backbone for Actimab-A. The ongoing Phase 1/2 trial of Actimab-A is in newly diagnosed AML patients over the age of 60 in a single arm multicenter trial.
Actinium to Present at 2nd Annual Sachs Cancer Bio Partnering & Investor Forum
Business Wire - Thu Mar 13, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at New York Academy of Sciences, located at 250 Greenwich St, New York, NY, on Wednesday, March 19, 2014 at 2:45 PM ET.
Actinium Files Annual Report on Form 10-K for the Year Ended December 31, 2013
Business Wire - Wed Mar 05, 6:00AM CST
--Highlights Achievements for 2013
Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Wed Feb 26, 11:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company", a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club of New York, located at 1 West 54th Street, New York, NY, on Monday, March 3, 2014 at 9:05 AM ET.
Actinium Announces Start of Collaboration to Manufacture Iomab(TM)-B for Phase 3 Clinical Trial and Commercialization
Business Wire - Tue May 06, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it made further steps towards centralized current good manufacturing practice ("cGMP" manufacturing of its lead drug candidate Iomab(TM)-B. The Company engaged IBA Molecular North America, Inc. to scale up under cGMPs, the production of Iomab(TM)-B and further develop and validate the quality control testing of the product. Actinium to Present at the Sidoti Micro-Cap Conference in NYC on May 9
Business Wire - Mon May 05, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will participate in the Sidoti Ninth Annual Micro-Cap Conference in New York City on May 9, 2014. Actinium Announces Key Additions to Senior Management Team
Business Wire - Mon Apr 28, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of four new additions to the senior management team. As Actinium's drug candidates continue to advance through the clinic, these hires are timely and expected to enable the Company to maximize the value of its assets. Capabilities are being added in clinical operations, regulatory affairs, quality assurance, finance and communications. Actinium gains business development and investor relations expertise as well, as the Company raises its profile in the investment community. These four hires bring to the Company a robust and complementary set of healthcare industry experience, product development skills, regulatory compliance, and communications acumen. Actinium to Present at RedChip Global Online CEO Conference April 24
Business Wire - Thu Apr 24, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 12:30 PM ET at RedChip's Global Online CEO Conference. Dr. Kaushik J. Dave, President and CEO will present a corporate update. RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Apr 17, 8:20AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, April 17, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, April 19, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Saturday, April 19, 2014 at 3:30 p.m. GMT, and Sunday, April 20, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday April 20, 2014 at 3:30 p.m. HKT. Actinium Pharmaceuticals, Inc. Analyst Report: High Potential Emerging Biopharmaceutical Firm Nearing Phase 3 Trial Commencement for Innovative Cancer Treatments
PR Newswire - Thu Apr 10, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications.
Actinium Announces Further Development of Actimab-A Manufacturing
Business Wire - Mon Apr 07, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it started a collaboration with IsoTherapeutics Group of Houston, TX to complete studies required for introduction of a new manufacturing process for Actimab-A. The new manufacturing process that results in a tenfold improvement of manufacturing yield has been developed by the Company internally in collaboration with IsoTherapeutics. IsoTherapeutics will perform additional experiments to generate documentation necessary for regulatory submissions. Actinium CEO Interviewed for "Small Stocks: Big Money" Airing on Fox Business and Bloomberg
Business Wire - Thu Apr 03, 12:15PM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces the availability of an exclusive interview with its President and CEO, Kaushik J. Dave, Ph.D. Actinium's shares listed on NYSE MKT to facilitate increased visibility and liquidity
M2 - Thu Mar 27, 5:14AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (NYSE MKT:ATNM) revealed on Wednesday that its shares have begun trading as of 26 March 2014 on the NYSE MKT under the symbol "ATNM".
Actinium Commences Trading on NYSE MKT Today under the Symbol ATNM
Business Wire - Wed Mar 26, 8:30AM CDT
Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that its shares have commenced trading today on the NYSE MKT under the symbol "ATNM". The company formerly traded on the OTCQB under the same symbol. Actinium to Commence Trading on NYSE MKT on March 26, 2014
Business Wire - Tue Mar 25, 9:05AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will commence trading its common shares on the NYSE MKT beginning on March 26, 2014. Actinium to Present at BioCentury 21st Annual Future Leaders in the Biotech Industry Conference on March 28
Business Wire - Tue Mar 25, 6:00AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the BioCentury 21st Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 8:30 am Eastern Time. Actinium to begin trading on NYSE MKT on 26 March 2014
M2 - Tue Mar 25, 4:16AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) disclosed on Monday that it will commence trading on the New York Stock Exchange on 26 March 22014.
Actinium Pharmaceuticals' Actimab-A drug candidate enters ongoing Phase 1/2 trial for newly diagnosed AML patients
M2 - Tue Mar 25, 4:06AM CDT
Biopharmaceutical company Actinium Pharmaceuticals (OTC BB:ATNM.OB) said on Monday that it has treated the first patient with Actimab-A drug candidate for newly diagnosed AML patients under its ongoing Phase 1/2 trial.
Actinium to List Common Stock on NYSE MKT
Business Wire - Mon Mar 24, 4:20PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on March 26, 2014. The Company will continue to trade under the symbol "ATNM" but will withdraw its shares from listing on the OTCQB concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies. Actinium Announces Introduction of the New Lot of Lintuzumab into the Clinic
Business Wire - Mon Mar 24, 4:10PM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the first patient was successfully treated with Actimab-A drug candidate manufactured with the new lot of Lintuzumab, the antibody that provides the backbone for Actimab-A. The ongoing Phase 1/2 trial of Actimab-A is in newly diagnosed AML patients over the age of 60 in a single arm multicenter trial. Actinium to Present at 2nd Annual Sachs Cancer Bio Partnering & Investor Forum
Business Wire - Thu Mar 13, 6:01AM CDT
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at New York Academy of Sciences, located at 250 Greenwich St, New York, NY, on Wednesday, March 19, 2014 at 2:45 PM ET. Actinium Files Annual Report on Form 10-K for the Year Ended December 31, 2013
Business Wire - Wed Mar 05, 6:00AM CST
--Highlights Achievements for 2013
Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Wed Feb 26, 11:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"
, a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club of New York, located at 1 West 54th Street, New York, NY, on Monday, March 3, 2014 at 9:05 AM ET. 
